

**COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION &
TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION**

ABSTRACT OF THE DISCLOSURE

A pharmaceutical composition comprises a surfactant and a nucleic acid comprising an oligonucleotide (oligo) anti-sense to an adenosine A1, A2a, A2b or A3 receptor gene, mRNA, flanking regions or regions bridging the intron/exon borders, low adenosine analogues which bind thymidine but exhibit lower or no adenosine receptor agonist activity. The composition and formulations thereof is effective for preventing and alleviating bronchoconstriction, allergy(ies) and/or inflammation and other conditions associated with breathing difficulties, impeded and obstructed airways, bronchoconstriction, allergy and/or inflammation, such as asthma, kidney damage or failure, acute respiratory distress syndrome (ARDS), inflammation, allergies, impeded respiration, respiratory distress syndrome (RDS), pain, cystic fibrosis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukemias, lymphomas, carcinomas, and the like, e.g. colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic, lung, breast, and prostate metastases, etc., to counter the renal damage and failure associated with ischemic conditions and the administration of certain drugs and radio active diagnostic and therapeutic agents, as well as a joint therapy with the administration of

adenosine and adenosine-like agents in the treatment of arrhythmias such as SVT and in cardiovascular function tests (stress tests). The present agent is administered alone or before, during and after other treatments, including radiation, chemotherapy, antibody therapy, phototherapy, other cancer treatments, and surgery, either preventatively, prophylactically or therapeutically.

s:\legal\EPI-072\Application EPI-00672 (-072) Substitute Cleaned up)